Prab: CSV import

2024-03-02T14:54:56Z

CSV import

New page

'''Romosozumab''' is a [[monoclonal antibody]] designed for the treatment of [[osteoporosis]]. It functions by inhibiting the protein [[sclerostin]], and has a dual effect of increasing bone formation and decreasing bone resorption.

== History ==

Romosozumab was developed by the biopharmaceutical companies [[Amgen]] and [[UCB]]. The drug was approved by the [[Food and Drug Administration|FDA]] in April 2019 under the brand name Evenity. It was also approved by the [[European Medicines Agency|EMA]] in December 2019.

== Mechanism of Action ==

Romosozumab works by binding to [[sclerostin]], a protein that inhibits bone formation. By inhibiting sclerostin, romosozumab allows for increased bone formation. Additionally, the drug also decreases bone resorption, the process by which osteoclasts break down bone and release the minerals, resulting in a transfer of calcium from bone fluid to the blood.

== Clinical Trials ==

Romosozumab has undergone several [[clinical trials]] to assess its safety and efficacy. The FRAME study, published in 2016, found that romosozumab significantly reduced the risk of vertebral fractures in postmenopausal women with osteoporosis. The ARCH study, published in 2017, found that romosozumab was superior to [[alendronate]] in reducing the risk of fractures.

== Side Effects ==

Common side effects of romosozumab include joint pain, headache, and injection site reactions. Serious side effects may include [[hypocalcemia]], [[osteonecrosis]] of the jaw, and atypical femoral fractures.

== See Also ==

* [[Monoclonal antibodies]]
* [[Osteoporosis]]
* [[Sclerostin]]
* [[Clinical trials]]

[[Category:Drugs]]
[[Category:Monoclonal antibodies]]
[[Category:Osteoporosis]]
{{Medicine-stub}}

Romosozumab - Revision history

Prab: CSV import